Category: Uncategorized

AHFS Drug Information/Essentials Update – August 2017

The August update to the AHFS Drug Information/Essentials database has been published. Highlights from this month’s update include:

New Full-Length Monographs

  • None

New First-Release Monographs

  • Trientine (Syprine®) – 64:00 (Heavy Metal Antagonists)
    • Indicated in the treatment of patients with Wilson’s disease who are intolerant of penicillamine
  • Delafloxacin (Baxdela®) – 8:12.18 (Quinolones)
    • Indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria
  • Betrixaban (Bevyxxa®) – 20:12.04.14 (Direct Factor Xa Inhibitors)
    • Indicated for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE
  • Naltrexone And Bupropion (Contrave®) – 28:20.08.92 (Anorexigenic Agents, Miscellaneous)
    • Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
  • Guselkumab (Tremfya®) – 84:92 (Skin and Mucous Membrane Agents, Miscellaneous)
    • Indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
  • L-Glutamine (Endari®) – 92:92 (Other Miscellaneous Therapeutic Agents)
    • Indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older

FDA MedWatch Alerts

  • None

AHFS Patient Medication Information Update – July 2017

The July update to the AHFS Patient Medication Information (PMI) database has been published. Highlights of the update include:

New PMI Monographs

  • Naldemedine (Symproic®)
    • Naldemedine is used to treat constipation caused by opioid (narcotic) pain medications in adults with chronic (ongoing) pain that is not caused by cancer.
  • Ammonium Lactate Topical (Lac-Hydrin®)
    • Ammonium lactate is used to treat xerosis (dry or scaly skin) and ichthyosis vulgaris (an inherited dry skin condition) in adults and children.
  • Telotristat (Xermelo®)
    • Telotristat is used in combination with another medication (a samotostatin analog [SSA] such as lanreotide, octreotide, pasinreotide) to control diarrhea caused by carcinoid tumors (slow-growing tumors that release natural substances that can cause symptoms like diarrhea) in patients with diarrhea not controlled by a somatostatin analog alone.
  • Durvalumab Injection (Imfinzi®)
    • Durvalumab injection is used to treat urothelial cancer (cancer of the lining of the bladder and other parts of the urinary tract) that spread to nearby tissues or other parts of the body that cannot be removed by surgery and has worsened during or after being treated with other chemotherapy medications.

FDA MedWatch Alert Revisions

  • None

AHFS Patient Medication Information Update – March 2017

The March update to the AHFS Patient Medication Information (PMI) database has been published. Highlights of the update include:

New PMI Monographs

  • Hydrocortisone Rectal (Anusol HC®, Colocort®, Cortenema®, Preparation H Anti-Itch®, Proctocort®, Proctofoam HC®)
    • Rectal hydrocortisone is used along with other medications to treat proctitis (swelling in the rectum) and ulcerative colitis (a condition which causes swelling and sores in the lining of the large intestine and rectum).
  • Lixisenatide Injection (Adlyxin®)
    • Lixisenatide injection is used along with diet and exercise to treat type 2 diabetes.
  • Cromolyn Ophthalmic (Crolom®)
    • Cromolyn ophthalmic is used to treat the symptoms of allergic conjunctivitis (a condition in which the eyes become itchy, swollen, red, and teary when they are exposed to certain substances) and keratitis (a condition that causes swelling of the cornea [tissue in the front of the eye] that causes eye redness, pain, and tearing and changes in vision).
  • Bezlotoxumab Injection (Zinplava®)
    • Bezlotoxumab injection is used to decrease the risk of Clostridium difficile infection (a type of bacteria that can cause severe or life-threatening diarrhea) from coming back in people at high risk for C. difficile infection.

FDA MedWatch Alert Revisions

FDA is warning that eluxadoline (Viberzi®), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder.

1 2